JPRN-jRCT2080221868未知2 期
A Multiple Dose, PhaseII Clinical Trial to Assess the Pharmacokinetics of KRP-AB1102 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
试验速览
- 阶段
- 2 期
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Adult male COPD patients aged >40, and others.
排除标准
- •- Current active tuberculopsis
- •- Patient hospitalized for an acute COPD exacerbation within the previous 3 months, and others.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaMedDRA version: 20.0Level: LLTClassification code 10000452Term: AchondroplasiaSystem Organ Class: 100000004850AchondroplasiaEUCTR2020-001189-13-DKPfizer Inc., 235 East 42nd Street, New York, NY 1001763
进行中（未招募）
1 期
Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaAchondroplasiaEUCTR2020-001189-13-PTPfizer Inc.57
进行中（未招募）
1 期
Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaMedDRA version: 20.0Level: LLTClassification code 10000452Term: AchondroplasiaSystem Organ Class: 100000004850AchondroplasiaEUCTR2020-001189-13-ITPFIZER INC63
已完成
2 期
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With AchondroplasiaAchondroplasiaJPRN-jRCT2061220040Kawai Norisuke63
进行中（未招募）
1 期
Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaMedDRA version: 25.0Level: LLTClassification code 10000452Term: AchondroplasiaSystem Organ Class: 100000004850AchondroplasiaEUCTR2020-001189-13-BEPfizer Inc., 235 East 42nd Street, New York, NY 1001757